Üremik Periferik Nöropati ve Kanıta Dayalı Tedavi Bakım Uygulamaları
Özet
Üremik periferik nöropati, böbrek yetmezliği sonucu gelişen ve sinir hasarına yol açan bir durumdur. Tedavi, altta yatan böbrek hastalığının yönetilmesini ve sinir hasarının semptomlarının hafifletilmesini içerir. Üremik periferik nöropatisi olan hastaların yaşam kalitesini artırmak için ağrı yönetimi, fizik terapi ve uygun ilaç kullanımı gerekmektedir. Erken teşhis ve bireyselleştirilmiş tedavi planları, nöropatinin ilerlemesini yavaşlatmada ve komplikasyonların önlenmesinde kritik öneme sahiptir. Hastaların düzenli takibi ve eğitimi, tedavi başarısını artırır ve uzun vadeli sonuçları iyileştirir. Hemşirelerin üremik periferik nöropatinin yönetiminde ve tedavisinde yadsınamaz aktif rolleri bulunmaktadır. Üremik periferik nöropatisi olan hastaların yaşam kalitelerinin artırılması ve komplikasyonların önlenmesi bakımından etkili hemşirelik bakımı gerekmektedir.
Referanslar
Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases. Oxford University Press; 2019. p. 1803-5.
World Health Organization. Non-communicable diseases. 2022 (Available from: https://www.who.int/health-topics/noncommunicable-diseases#tab=tab_1).
Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The lancet. 2020;395(10225):709-33.
Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. The lancet. 2016;388(10053):1459-544.
Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. The Lancet. 2018;392(10159):2052-90.
US National Institute of Diabetes and Digestive and Kidney Diseases. Kidney disease statistics for the United States. 2023 [Available from:https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease.
Krishnan AV, Kiernan MC. Neurological complications of chronic kidney disease. Nature Reviews Neurology. 2009;5(10):542-51.
Anbarasu D, Prathiba P. Study on prevalence of peripheral neuropathy among patients on hemodialysis. IAIM. 2018;5(10):73-80.
Brouns R, De Deyn P. Neurological complications in renal failure: a review. Clinical neurology and neurosurgery. 2004;107(1):1-16.
Camargo CRSd, Schoueri JHM, Alves BdCA, Veiga GRd, Fonseca FL, Bacci MR. Uremic neuropathy: an overview of the current literature. Revista da Associação Médica Brasileira. 2019;65(3):469-74.
Yu X-z, Lu S, Gou W, Wang W, Zou S-h, Yin-xia H, et al. Assessment of the characteristics and quality of life of patients with uremic peripheral neuropathy. Clinical Nephrology. 2017;87(3):134.
Wiesman JF. Peripheral Neuropathy: What It Is and What You Can Do to Feel Better: JHU Press; 2016.
Vaziri D, Pratt H, Saiki JK, et al. Evaluation of somatosensory pathway by short latency evoked potentials in patients with end-stage renal disease maintained on hemodialysis. Int J Artif Organs. 1981;4(1):17–22.
Kiernan MC, Walters RJ, Andersen KV, et al. Nerve excitability changes in chronic renal failure indicate membrane depolarization due to hyperkalaemia. Brain. 2002;125(Pt 6):1366–1378.
Krishnan AV, Phoon RK, Pussell BA, et al. Ischaemia induces paradoxical changes in axonal excitability in end-stage kidney disease. Brain. 2006;129(Pt 6):1585–1592.
Panjwani M, Truong LD, Eknoyan G. Membranous glomerulonephritis associated with inflammatory demyelinating peripheral neuropathies. Am J Kidney Dis. 1996;27(2):279–283.
Oh SJ, Clements RS Jr, Lee YW, et al. Rapid improvement in nerve conduction velocity following renal transplantation. Ann Neurol.1978;4(4):369–373.
Meyer TW, Hostetter TH. Uremia. N Engl J Med. 2007;357(13):1316–1325.
Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038–2047.
Barsoum RS. Chronic kidney disease in the developing world. N Engl J Med. 2006;354(10):997–999.
Baumgaertel MW, Kraemer M, Berlit P. Neurologic complications of
acute and chronic renal disease. Handb Clin Neurol.2014;119:383–393.
Pietrzak I, Baczyk K. Erythrocyte transketolase activity and guanidino compounds in hemodialysis patients. Kidney Int Suppl.2001;78:S97–101.
Bolton CF. Electrophysiologic changes in uremic neuropathy after
successful renal transplantation. Neurology. 1976;26(2):152–161.
Pan Y. Uremic neuropathy. MedLink Neurology. 2006.
Pina-Escudero S. Uremic Neuropathy. Pain: Oxford Academic; 2022.
Kang A, Arnold R, Gallagher M, Snelling P, Green J, Fernando M, et al. Effect of hemodiafiltration on the progression of neuropathy with kidney failure: a randomized controlled trial. Clin J Am Soc Nephrol. 2021;16(9):1365–75.
Khafagi AT, Yehia MA, Helmy AK, Elzanaty RM. Effect of erythropoietin-stimulating agent on uremic neuropathy in hemodialysis patients: a single-center open-label prospective study. Egypt J Neurol Psychiatry Neurosurg. 2022;58:53.
Ferdousi M, Azmi S, Kalteniece A, Khan SU, Petropoulos IN, Ponirakis G, et al. No evidence of improvement in neuropathy after renal transplantation in patients with end stage kidney disease. J Peripher Nerv Syst. 2021;26(3):269–75.
Strempska B, Bilinska M, Weyde W, Koszewicz M, Madziarska K, Golebiowski T, et al. The effect of high-tone external muscle stimulation on symptoms and electrophysiological parameters of uremic peripheral neuropathy. Clin Nephrol. 2013;79(Suppl 1):S24–7.
Ceylan, H., Yangöz, Ş. T., & Özer, Z. (2024). Coping strategies and its relationship with sexual dysfunction in adults receiving haemodialysis and peritoneal dialysis: A cross-sectional study. Journal of Clinical Nursing, 33, 1421–1431. https://doi.org/10.1111/jocn.16930
